[HTML][HTML] PRMT5 function and targeting in cancer
H Kim, AR Ze'ev - Cell stress, 2020 - ncbi.nlm.nih.gov
Protein methyl transferases play critical roles in numerous regulatory pathways that underlie
cancer development, progression and therapy-response. Here we discuss the function of …
cancer development, progression and therapy-response. Here we discuss the function of …
[HTML][HTML] MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
LD Engstrom, R Aranda, L Waters, K Moya, V Bowcut… - Cancer discovery, 2023 - AACR
Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic
lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic …
lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic …
[HTML][HTML] MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage
The methylthioadenosine phosphorylase (MTAP) gene is located adjacent to the cyclin-
dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with …
dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with …
PRMTs and arginine methylation: cancer's best-kept secret?
J Jarrold, CC Davies - Trends in molecular medicine, 2019 - cell.com
Post-translational modification (PTM) of proteins is vital for increasing proteome diversity
and maintaining cellular homeostasis. If the writing, reading, and removal of modifications …
and maintaining cellular homeostasis. If the writing, reading, and removal of modifications …
[HTML][HTML] PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer
Y Wu, Z Wang, L Han, Z Guo, B Yan, L Guo, H Zhao… - Molecular Therapy, 2022 - cell.com
Cancer cells respond to various stressful conditions through the dynamic regulation of RNA
m6A modification. Doxorubicin is a widely used chemotherapeutic drug that induces DNA …
m6A modification. Doxorubicin is a widely used chemotherapeutic drug that induces DNA …
[HTML][HTML] MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
K Marjon, MJ Cameron, P Quang, MF Clasquin… - Cell reports, 2016 - cell.com
Homozygous deletions of p16/CDKN2A are prevalent in cancer, and these mutations
commonly involve co-deletion of adjacent genes, including methylthioadenosine …
commonly involve co-deletion of adjacent genes, including methylthioadenosine …
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
BJ Wouters, R Delwel - Blood, The Journal of the American …, 2016 - ashpublications.org
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is
a heterogeneous malignancy characterized by distinct genetic abnormalities. Recent …
a heterogeneous malignancy characterized by distinct genetic abnormalities. Recent …
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Protein arginine methyltransferase 5 (PRMT5) controls diverse cellular processes and is
implicated in cancer development and progression. Here, we report an inverse correlation …
implicated in cancer development and progression. Here, we report an inverse correlation …
[HTML][HTML] The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD
G Günes Günsel, TM Conlon, A Jeridi, R Kim… - Nature …, 2022 - nature.com
Extravasation of monocytes into tissue and to the site of injury is a fundamental
immunological process, which requires rapid responses via post translational modifications …
immunological process, which requires rapid responses via post translational modifications …